Palleon Pharmaceuticals
Waltham
About Palleon Pharmaceuticals
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $147.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2020)
- Website: palleonpharma.com
- Phone: (508)479-6358
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/palleon-pharmaceuticals-87023 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.